Vitrectomy outcomes are affected by retinoschisis in myopic macular holes

Article

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis.

Vitrectomy used to treat highly myopic macula holes (HMMHs) is negatively affected by retinoschisis, claims a study in the British Journal of Ophthalmology.

Dr Yasushi Ikuno et al., Department of Ophthalmology, Osaka University Medical School, Yamadaoka, Japan, performed a retrospective cross-sectional study on 22 eyes with HMMHs that underwent vitrectomy.

All eyes were split into two groups. Ten eyes were identified with retinoschisis and 12 did not have retinoschisis. Posterior staphyloma height was measured by optical coherence tomography (OCT). The surgical outcomes were postoperative final best-corrected visual acuity (BCVA) and reoperation rate.

Postoperative BCVA was strongly linked to presence or absence of retinoschisis and preoperative BCVA. The schisis group presented with a worse visual acuity and a greater posterior staphyloma height than the non-schisis group.

Highly myopic eyes presented with two types of macula holes with significantly different prognosis. The investigation suggests the careful interpretation of preoperative OCT images to identify accurate surgical results.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.